Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Cancer of the Prostate or Prostate Cancer
and you are
over 18
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The purpose of this trial is to test if the combination of enzalutamide and metformin in patients with castration resistant prostate cancer CRPC progressing on androgen deprivation therapy ADT is more effective compared to enzalutamide alone. The half of the patients will receive the experimental treatment combination, enzalutamide and metformin, while the other half will receive enzalutamide alone.

Provided treatments

  • Drug: Enzalutamide
  • Drug: Metformin
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02640534. The sponsor of the trial is Swiss Group for Clinical Cancer Research and it is looking for 168 volunteers for the current phase.
Official trial title:
Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone (IMPROVE TRIAL): A Randomized, Open Label, Phase II Trial